会议注册与报到报到注册时间 :2016 年 11 月 10 日报到及会议地点 : 上海药物所承嘏厅, 上海市浦东张江高科祖冲之路 555 号会议注册费 : 免费 ( 每家单位限额 2 名参会人员

Size: px

Start display at page:

Download "会议注册与报到报到注册时间 :2016 年 11 月 10 日报到及会议地点 : 上海药物所承嘏厅, 上海市浦东张江高科祖冲之路 555 号会议注册费 : 免费 ( 每家单位限额 2 名参会人员"

命卜
7 years ago
Views:

1 第三届 SIMM-AZ 新药创制高层学术研讨会主题 : 新药创制高层研讨会研发策略与新技术应用 The development and application of emerging technologies in the discovery of safer medicines. 时间 :2016 年 11 月 10 日, 上海浦东, 上海药物所承嘏厅为适应我国创新药物研发不断增长的需求, 中国科学院上海药物研究所阿斯利康 () 与上海药物研究所 - 阿斯利康药物安全性评价联盟联合举办的第三届新药创制高层学术研讨会, 将于 2016 年 11 月 10 日在上海举行, 会期一天本届研讨会以阿斯利康公司代表性的新药研发成功案例 Osimertininb ( 奥希替尼, AZD9291)--- 第三代 EGFR 抑制剂的研发经历为主题, 围绕着新药创制研发策略与新技术应用的热点和难点问题, 从不同侧面进行深入的剖析式学术交流研讨会的主题如下 : 1. Perspectives on the discovery of innovative medicines: challenges, emerging scientific innovations and future opportunities 2. The journey of Osimertininb (AZD9291) from bench to clinic (including patient selection) 3. Fundamentals of hepatobiliary system and relevance to drug toxicity 4. Topic relating to hepatic safety and ADME with case studies 5. Topic relating to pharmacogenetics and DDI with case studies 6. Topics by SIMM,TBD 期待与您相聚上海! 共同推动我国生物制药产业的创新和发展! 中国科学院上海药物研究所 ( 药物安全评价研究中心 ) 上海药物研究所 - 阿斯利康药物安全性评价联盟中国药学会毒性病理专委会 2016 年 9 月 13 日

会, 将于 2016 年 11 月 10 日在上海举行, 会期一天本届研讨会以阿斯利康公司代表性的新药研发成功案例 Osimertininb ( 奥希替尼, AZD9291)--- 第三代 EGFR 抑制剂的研发经历为主题, 围绕着新药创制研发策略与新技术应用的热

2 会议注册与报到报到注册时间 :2016 年 11 月 10 日报到及会议地点 : 上海药物所承嘏厅, 上海市浦东张江高科祖冲之路 555 号会议注册费 : 免费 ( 每家单位限额 2 名参会人员 ) 联系人及联系方式 : 李明 workshop@cdser.simm.ac.cn 会议代表的注册, 可以通过填写会议回执, 邮寄或发电子邮件至联系人处参会代表自行安排住宿 ; 代表可联系药物所协议酒店博雅酒店, 上海市浦东张江碧波路 699 号, 下图 A 所示 ( 地铁二号线张江高科站下,5 号出口, 步行 5 分钟即可 ):

cn 13917417756 会议代表的注册, 可以通过填写会议回执, 邮寄或发电子邮件至联系人处参会代表自行安排住宿 ; 代表

3 参会回执单位 : 参会人员 1 姓名 : 性别 : 职称 / 职务 : 联系电话 : 参会人员 2 姓名 : 性别 : 职称 / 职务 : 联系电话 : 备注 :

4 会议议程 Agenda Nov 10, 2016 Morning Dr. Stefan Plaz, Dr. Mark Anderton, Dr Paul Morgan, PROGRAM 议程 Opening Speech Perspectives on the discovery of innovative medicines: challenges, emerging scientific innovations and future opportunities The journey of Osimertininb (AZD9291) from bench to clinic (including patient selection) Topic relating to hepatic safety and ADME with case studies Q&A Afternoon Dr. Mark Anderton, Dr Paul Morgan, Dr. TBD, SIMM Fundamentals of hepatobiliary system and relevance to drug toxicity Topic relating to pharmacogenetics and DDI with case studies Q&A Wrap up

innovations and future opportunities The journey of Osimertininb (AZD9291) from bench to clinic (including patient selection) Topic relating to

5 演讲者介绍 Introdution of Speakers DR Stefan Platz, DVM, PhD, DABT, Vice President of Drug Safety and Metabolism Stefan Platz is the Vice President of Drug Safety and Metabolism within s Innovative Medicines and Early Development unit. In this role, Stefan is responsible for Toxicology, Pathology, DMPK and Laboratory Animal Sciences and leads a global team across Sweden, UK and the US. He is particularly interested in exploring novel approaches and technologies to improve the understanding of human safety risks prior to testing in clinical trials. Stefan has a degree in veterinary from the University of Munich and is a German certified veterinary pathologist and Diplomate of the American Board of Toxicology. He started his career in 1996 at Boehringer Ingelheim with short term secondments at the Ohio State University and the Pembroke College in Cambridge. In 2001 he contributed to the successful filing to Tenecteplase, a tissue plasminogen activator. Before joining in February 2012, Stefan led the non-clinical safety organisations for Hoffmann-La Roche in both Basel and Palo Alto, and had extended periods of responsibilities for the early safety and biologics safety strategies.

He is particularly interested in exploring novel approaches and technologies to improve the understanding of human safety risks prior to testing in clinical trials.

6 Dr Paul Morgan, head of Safety and ADME Translational Sciences, Paul gained his BSc degree and PhD at the University of Liverpool, UK in Chemistry and Pharmacology. His PhD explored the SAR of novel estrogen analogues at the pharmacology, metabolism and safety interface. After his PhD, Paul joined Pfizer Research & Development in UK in 1991 working in the DMPK department where he gained experience in all aspects of support in drug discovery and development across multiple therapeutic areas. Paul had a number of site and global DMPK leadership roles during his time at Pfizer and contributed to the registration and launch of a number of products including Relpax, Viagra, Selzentry and Xalkori. In 2011, Paul joined in UK as leader of the global DMPK Centre of Excellence which brought oversight to the DMPK science strategies in support of all disease areas. In 2013 Paul helped to establish the Drug Safety and Metabolism function merging safety assessment and DMPK. Paul s current role is head of Safety and ADME Translational Sciences where quantitative, translational models are developed employing safety, DMPK and PKPD expertise to improve target organ safety risk assessment in discovery and development projects.

After his PhD, Paul joined Pfizer Research & Development in UK in 1991 working in the DMPK department where he gained experience in all aspects of support in drug discovery and development across

7 Dr Mark Anderton Mark received his 1st Class honours degree in Pharmacology from University of Leeds (UK) followed by a PhD in Cancer Pharmacology from the Medical Research Council Toxicology Unit (Leicester, UK). After his PhD, Mark joined Vertex Pharmaceuticals (UK) where he worked as the lead Project Pharmacologist within drug discovery teams. In 2008, Mark joined where he is now a Principal Scientist within the Drug Safety and Metabolism Department. Marks main role is a Discovery Toxicologist where he works within drug discovery research teams to mitigate safety liabilities and influence candidate drug selection. Marks expertise is within the oncology therapy area where he has over 10 years experience working in oncology drug discovery project teams. One of Marks notable successes at has been mitigating safety liabilities and influencing the selection of candidate compound AZD9291/Tagrisso, a recently approved treatment option for locally advanced or metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer. In addition to his role within drug safety, Mark is also a drug discovery project leader where he leads a multidisciplinary team to discover new medicines.

In 2008, Mark joined where he is now a Principal Scientist within the Drug Safety and Metabolism Department.

Microsoft Word - 工业品封面.doc

Microsoft Word - 工业品封面.doc 工业品专刊浙江出入境检验检疫局政策研究室 (WTO 研究室 ) 2010 年 05 月 27 日目录工作动态浙江检验检疫局专家参加欧盟洗衣机洗碗机能效及生态设计通报评议会 1 浙江检验检疫局举办出口玩具检验监管工作研讨会 2 台州出口鞋

会 议 注 册 与 报 到 报 到 注 册 时 间 :2016 年 11 月 10 日 报 到 及 会 议 地 点 : 上 海 药 物 所 承 嘏 厅, 上 海 市 浦 东 张 江 高 科 祖 冲 之 路 555 号 会 议 注 册 费 : 免 费 ( 每 家 单 位 限 额 2 名 参 会 人 员

会议注册与报到报到注册时间 :2016 年 11 月 10 日报到及会议地点 : 上海药物所承嘏厅, 上海市浦东张江高科祖冲之路 555 号会议注册费 : 免费 ( 每家单位限额 2 名参会人员